Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial

Area of Science:

• Cardiology
• Pharmacology
• Medical Imaging

Background:

• Calcific aortic stenosis (CAS) is a progressive disease.
• Coronary artery calcification (CAC) is a marker of atherosclerosis.
• The role of lipid-lowering therapy in CAS progression is debated.

Purpose of the Study:

• To assess the effect of intensive lipid-lowering treatment with atorvastatin on CAC progression in patients with CAS.
• To evaluate the impact of atorvastatin on systemic inflammation markers.

Main Methods:

• A double-blind, randomized controlled trial involving 102 patients with CAS and CAC.
• Patients received either atorvastatin 80 mg daily or placebo.
• CAC was quantified annually using helical computed tomography over a median follow-up of 24 months.

Main Results:

• Atorvastatin significantly reduced low-density lipoprotein cholesterol (LDL-C) by 53% and C-reactive protein (CRP) by 49%.
• The rate of CAC progression was 26%/year in the atorvastatin group versus 18%/year in the placebo group (p=0.18).
• No significant correlation was found between LDL-C levels and the rate of CAC progression.

Conclusions:

• Intensive statin therapy, despite lowering LDL-C and CRP, did not significantly alter the rate of coronary artery calcification progression in patients with calcific aortic stenosis.
• Findings contrast with previous observational studies, suggesting statins may not be effective in slowing CAC progression in this specific population.